Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects

Antiviral Research

Volumn 83, Issue 2, 2009, Pages 118-126

  Monno, Laura ^a   Scudeller, Luigia ^b   Brindicci, Gaetano ^a   Saracino, Annalisa ^c   Punzi, Grazia ^a   Chirianni, Antonio ^d   Lagioia, Antonella ^a   Ladisa, Nicoletta ^a   Caputo, Sergio Lo ^e   Angarano, Gioacchino ^c  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^e Hospital Santa Maria Annunziata   (Italy)

Author keywords

HIV 1; Non B subtypes; Resistance

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RNA, VIRAL; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349284100     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.04.001     Document Type: Article

References (36)

1. Abecasis A.B., Deforche K., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., Vandamme A.M., and Camacho R.J. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 11 (2006) 581-589
2. Balotta C., Facchi G., Violin M., Van Dooren S., Cozzi-Lepri A., Forbici F., Bertoli A., Riva C., Senese D., Caramello P., Carnevale G., Rizzardini G., Cremonini L., Monno L., Rezza G., Perno C.F., Ippolito G., d'Arminio-Monforte A., Vandamme A.M., and Moroni M. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27 (2001) 499-505
3. Bannister W.P., Ruiz L., Loveday C., Vella S., Zilmer K., Kjaer J., Knysz B., Phillips A.N., and Mocroft A. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir. Ther. 11 (2006) 707-715
4. Bocket L., Cheret A., Deuffic-Burban S., Choisy P., Gerard Y., de la Tribonnière X., Viget N., Ajana F., Goffard A., Barin F., Mouton Y., and Yazdanpanah Y. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir. Ther. 10 (2005) 247-254
5. Brenner B.G., Oliveira M., Doualla-Bell F., Moisi D.D., Ntemgwa M., Frankel F., Essex M., and Wainberg M.A. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20 (2006) F9-13
6. Calazans A., Brindeiro R., Brindeiro P., Verli H., Arruda M.B., Gonzalez L.M., Guimaraes J.A., Diaz R.S., Antunes O.A., and Tanuri A. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J. Infect. Dis. 191 (2005) 1961-1970
7. Carr J.K., Salminen M.O., Koch C., Gotte D., Artenstein A.W., Hegerich P.A., St Louis D., Burke D.S., and McCutchan F.E. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J. Virol. 70 (1996) 5935-5943
8. Ceccherini-Silberstein F., Gago F., Santoro M., Gori C., Svicher V., Rodríguez-Barrios F., d'Arrigo R., Ciccozzi M., Bertoli A., d'Arminio Monforte A., Balzarini J., Antinori A., and Perno C.F. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J. Virol. 79 (2005) 10718-10729
9. De Wit S., Boulmé R., Poll B., Schmit J.C., and Clumeck N. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naïve HIV-1 patients. AIDS 18 (2004) 2330-2331
10. Dumans A.T., Soares M.A., Machado E.S., Hué S., Brindeiro R.M., Pillay D., and Tanuri A. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J. Infect. Dis. 189 (2004) 1232-1238
11. Gao F., Robertson D.L., Morrison S.G., Hui H., Craig S., Decker J., Fultz P.N., Girard M., Shaw G.M., Hahn B.H., and Sharp P.M. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70 (1996) 7013-7029
12. Greenacre M. Correspondence analysis in medical research. Stat. Methods Med. Res. 1 (1992) 97-117
13. Gupta R.K., Chrystie I.L., O'Shea S., Mullen J.E., Kulasegaram R., and Tong C.Y. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 19 16 (2005) 1916-1919
14. Holguín A., Suñe C., Hamy F., Soriano V., and Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J. Clin. Virol. 36 (2006) 264-271
15. Johnson V.A., Brun-Vézinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: Spring 2008. HIV Med. 16 (2008) 62-68
16. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Soares M.A., Snoeck J., Pillay C., Rudich H., Rodrigues R., Holguin A., Ariyoshi K., Bouzas M.B., Cahn P., Sugiura W., Soriano V., Brigido L.F., Grossman Z., Morris L., Vandamme A.M., Tanuri A., Phanuphak P., Weber J.N., Pillay D., Harrigan P.R., Camacho R., Schapiro J.M., and Shafer R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2 (2005) e112
17. Konings F.A., Zhong P., Agwara M., Agyingi L., Zekeng L., Achkar J.M., Ewane L., Saa, Afane Ze E., Kinge T., and Nyambi P.N. Protease mutations in HIV-1 non-B strains infecting drug-naïve villagers in Cameroon. AIDS Res. Hum. Retroviruses 20 (2004) 105-109
18. McGrath D., Wirtz V., Yang R., Mathew M., Rightmire A., Schnittman S., and for the BMS AI424089 Study Group. Antiviral efficacy and emergent PI substitutions in treatment-naïve subjects receiving atazanavir +/- ritonavir-based HAART in subtype B and non-type B HIV-1 infection. Antivir. Ther. 12 (2007) S90
19. Mihailidis C., Dunn D., Pillay D., and Pozniak A. Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy. AIDS 22 (2008) 427-432
20. Monno L., Brindicci G., Lo Caputo S., Punzi G., Scarabaggio T., Riva C., Di Bari C., Pierotti P., Saracino A., Lagioia A., Mazzotta F., Balotta C., and Angarano G. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J. Med. Virol. 75 (2005) 483-490
21. Parkin, N.T., Chappey, C., Petropoulos, C.J. 2002. Mutations in HIV-1 protease associated with resistance to amprenavir contribute towards phenotypic resistance to lopinavir. Int. Conf. AIDS 2002 July 7-12; 14: abstract TuPeB4613.
22. Perez-Elias M.J., Garcia-Arota I., Muñoz V., Santos I., Sanz J., Abraira V., Arribas J.R., González J., Moreno A., Dronda F., Antela A., Pumares M., Martí-Belda P., Casado J.L., Geijos P., and Moreno S. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir. Ther. 8 (2003) 577-584
23. Perno C.F., Cozzi-Lepri A., Balotta C., Forbici F., Violin M., Bertoli A., Facchi G., Pezzotti P., Cadeo G., Tositti G., Pasquinucci S., Pauluzzi S., Scalzini A., Salassa B., Vincenti A., Phillips A.N., Dianzani F., Appice A., Angarano G., Monno L., Ippolito G., Moroni M., and d' Arminio Monforte A. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naïve patients treated with protease inhibitor-based therapy. J. Infect. Dis. 184 (2001) 983-991
24. Rhee S.-Y., Liu T., Ravela J., Gonzales M.J., and Shafer R.W. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4183 persons undergoing genotypic resistance testing. Antimicrob. Agents Chemother. 48 (2004) 3122-3126
25. Rhee S.Y., Fessel W.J., Zolopa A.R., Hurley L., Liu T., Taylor J., Nguyen D.P., Slome S., Klein D., Horberg M., Flamm J., Follansbee S., Schapiro J.M., and Shafer R.W. HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis. 192 (2005) 456-465
26. Rhee S.Y., Kantor R., Katzenstein D.A., Camacho R., Morris L., Sirivichayakul S., Jorgensen L., Brigido L.F., Schapiro J.M., and Shafer R.W. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIV seq program to seven non-B subtypes. AIDS 20 (2006) 643-651
27. Røge B.T., Katzenstein T.L., Obel N., Nielsen H., Kirk O., Pedersen C., Mathiesen L., Lundgren J., and Gerstoft J. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8 (2003) 173-182
28. Romano L., Venturi G., Bloor S., Harrigan R., Larder B.A., Major J.C., and Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185 (2002) 898-904
29. Saracino A., Monno L., Scudeller L., Cibelli D.C., Tartaglia A., Punzi G., Torti C., Lo Caputo S., Mazzotta F., Scotto G., Carosi G., and Angarano G. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. J. Med. Virol. 78 (2006) 9-17
30. Stanford University, Drug Resistance Database. http://hivdb. stanford.edu/ [accessed 17 October 2007].
31. Svarovskaia E.S., Feng J.Y., Margot N.A., Myrick F., Goodman D., Ly J.K., White K.L., Kutty N., Wang R., Borroto-Esoda K., and Miller M.D. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48 (2008) 428-436
32. van de Vijver D., Wensing A., Angarano G., Åsjö B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., Op de Coul E.L., De Luca A., Maljkovic I., de Mendoza C., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hoepelman I.M., Hemmer R., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Meyer L., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., Boucher C.A.B., and on behalf of the SPREAD Programme. Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to PI. Antivir. Ther. 10 (2005) S145
33. van de Vijver D.A., Wensing A.M., Angarano G., Asjö B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Maljkovic I., de Mendoza C., Meyer L., Nielsen C., Op de Coul E.L., Ormaasen V., Paraskevis D., Perrin L., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., and Boucher C.A.B. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41 (2006) 352-360
34. Vandamme A.M., Deforche K., Van Laethem K., and Camacho R. HIV-1 subtype A, C F and G strains have a higher tipranavir mutation score than subtype B strains. Antivir. Ther. 10 Suppl. (2005) 152
35. Vergne L., Peeters M., Mpoudi-Ngole E., Bourgeois A., Liegeois F., Toure-Kane C., Mboup S., Mulanga-Kabeya C., Saman E., Jourdan J., Reynes J., and Delaporte E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naïve patients. J. Clin. Microbiol. 38 (2000) 3919-3925
36. Vingerhoets J., Buelens A., Peeters M., Picchio G., Tambuyzer L., Cao Van K., De Smedt G., Woodfall B., and de Bethune M.P. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir. Ther. 12 (2007) S34